Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SH006 injection plus combination therapy vs regorafenib for advanced hepatocellular carcinoma
CTR20260323Phase 3Active
- Sponsor
- Shenghe Pharmaceutical
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SH006 in hepatocellular carcinoma (HCC), sponsored by Shenghe Pharmaceutical. Started Jan 2026; status: active.
02
Drugs
SH006
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20260323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260323.